Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

Proceedings of the National Academy of Sciences of the United States of America
Steven A Rosenberg, Mark E Dudley

Abstract

Our recent clinical trials demonstrate that autologous cell transfer after lymphodepleting chemotherapy can cause the regression of large, vascularized tumors in patients with refractory metastatic melanoma. Eighteen of 35 patients treated with tumor-reactive lymphocyte cultures experienced an objective clinical response (>50% reduction in tumor), including four complete responders. In some patients, tumor regression was accompanied by a large in vivo expansion of the administered antitumor lymphocytes, which persisted in peripheral blood at >70% of total lymphocytes for many months after transfer. The cells capable of mediating tumor regression consisted of heterogeneous lymphocyte populations with high avidity for tumor antigens that were derived from tumor-infiltrating lymphocytes cultured for limited times in vitro. The success of this treatment likely results from the ability to infuse large numbers of activated antitumor lymphocytes into an appropriate host homeostatic environment depleted of regulatory T cells. These studies are elucidating the requirements for successful immunotherapy of patients with advanced metastatic disease and are leading to additional clinical trials with gene-modified lymphocytes.

References

Jul 5, 1994·Proceedings of the National Academy of Sciences of the United States of America·Y KawakamiS A Rosenberg
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·Y KawakamiS A Rosenberg
Nov 21, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·K Liu, S A Rosenberg
Aug 20, 2003·The Journal of Experimental Medicine·Willem W OverwijkNicholas P Restifo
Sep 3, 2003·Nature Reviews. Cancer·Mark E Dudley, Steven A Rosenberg
Sep 10, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Richard A MorganSteven A Rosenberg

❮ Previous
Next ❯

Citations

Aug 10, 2010·Archivum Immunologiae Et Therapiae Experimentalis·Marek Jakóbisiak, Jakub Gołab
Dec 21, 2010·European Journal of Nuclear Medicine and Molecular Imaging·Luisa OttobriniGiovanni Lucignani
Feb 10, 2006·Cancer Immunology, Immunotherapy : CII·Helena HarlinThomas F Gajewski
May 12, 2005·Cancer Immunology, Immunotherapy : CII·Johannes ScheteligMartin Bornhäuser
Mar 24, 2006·Cancer Immunology, Immunotherapy : CII·Deepak P AssudaniRobert C Rees
Sep 9, 2006·Cancer Immunology, Immunotherapy : CII·Teresa CabreraFederico Garrido
Mar 17, 2010·Cancer Immunology, Immunotherapy : CII·Hui Zhang, Gary G Meadows
Jun 11, 2011·Cancer Immunology, Immunotherapy : CII·Manjunatha Ankathatti MunegowdaJim Xiang
May 5, 2005·Current Treatment Options in Oncology·Ehab Atallah, Lawrence Flaherty
Mar 16, 2005·Current Opinion in Immunology·Willem W Overwijk
Sep 6, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Yangbing ZhaoRichard A Morgan
Jan 5, 2005·The Lancet Oncology·Nicholas P Restifo, Steven A Rosenberg
Feb 1, 2005·Nature Medicine·John M Timmerman, Ronald Levy
Apr 18, 2008·Nature Reviews. Cancer·Cornelis J M Melief, Sjoerd H van der Burg
Feb 15, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Julie R ParkMichael C Jensen
Jul 20, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Hans J StaussEmma C Morris
Sep 17, 2008·Proceedings of the National Academy of Sciences of the United States of America·Brian A RabinovichPatrick Hwu
Oct 27, 2005·Cancer Biotherapy & Radiopharmaceuticals·Su-hu LiuWang-Gang Zhang
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
May 13, 2008·Human Gene Therapy·Duane A MitchellJohn H Sampson
Oct 15, 2005·Journal of Immunotherapy·Qiong J WangJames C Yang
Oct 15, 2005·Journal of Immunotherapy·Christian S HinrichsNicholas P Restifo
Jun 27, 2006·Journal of Immunotherapy·Yangbing ZhaoRichard A Morgan
Feb 3, 2007·Current Opinion in Oncology·Jedd D Wolchok, Yvonne M Saenger
Dec 31, 2010·Current Opinion in Oncology·Jeffrey Weber
Aug 2, 2007·Journal of Immunotherapy·Hans J J van der VlietMark A Exley
Dec 17, 2009·The Cancer Journal·Qing Yi
May 10, 2006·Immunology and Cell Biology·Siok-Keen TeyHelen E Heslop
Jun 8, 2012·Pigment Cell & Melanoma Research·Russell R BraeuerMenashe Bar-Eli
Mar 23, 2006·Annual Review of Immunology·Thierry BoonPierre van der Bruggen
Nov 30, 2006·Annual Review of Immunology·Ann M LeenAaron E Foster

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.